In cell and animal studies, it acts as a selective inhibitor of nicotinamide Nmethyltransferase (NNMT)
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
Persistent or worsening symptoms should be reported to the prescribing provider immediately
When gastrointestinal symptoms occur, they often relate to supplement formulation, excipients, or underlying health conditions rather than the vitamin itself
Apr 28th, 2026 Ipamorelin for natural growth hormone boost Ipamorelin is a synthetic growth hormonereleasing peptide that stimulates GH release via the ghrelin receptor, but human evidence is limited, and it is not FDA-approved, making its safety and effectiveness in healthy individuals uncertain
